Pharmaceutical

Beacon secures $170m to advance ophthalmic gene therapies

Beacon’s lead candidate AGTC-501 is currently in a Phase II/III clinical trial for the treatment of X-linked retinitis pigmentosa (XLRP).

Jul 4, 2024 - 04:00
Beacon secures $170m to advance ophthalmic gene therapies
Beacon’s lead candidate AGTC-501 is currently in a Phase II/III clinical trial for the treatment of X-linked retinitis pigmentosa (XLRP).
Read the original article

Tags:

Previous Article

Mapping the surfaces of MXenes, atom by atom, reveals new potential for the 2D m...

Next Article

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Liver specialist Aligos scores $92m in private placement funding

Liver specialist Aligos scores $92m in private placemen...

Oct 23, 2023

Opinion: Why brain decoding is not mind reading — and why that matters

Opinion: Why brain decoding is not mind reading — and w...

Jun 8, 2023

Listen: SVB’s long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

Listen: SVB’s long biotech shadow, pushy AI algorithms,...

Mar 19, 2023